DDrare: Database of Drug Development for Rare Diseases

279. 巨大静脈奇形（頚部口腔咽頭びまん性病変）
［臨床試験数：12，薬物数：23（DrugBank：9），標的遺伝子数：3，標的パスウェイ数：103］

Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Alcohol; Bleomycin; Bleomycin + Fibrovein; Bleomycin Baxter; Dehydrated Alcohol (Absolute Alcohol) BP for Injection; ETHANOL (96 PER CENT); ETHANOL BP; Ethanol; Ethanol 96% Gel; Ethanol 98% Solution; Ethanol gel; Ethanolamine; Ethanolamine oleate; Fibrovein; Fibrovein 3%; Iopamiron; L0122; Polidocanol; Rapamycin; Sirolimus; Trametinib; Trametinib tablet; VT30

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs071180067	23/10/2009	20/03/2019	Clinical research of intralesional sclerotherapy in the oral and maxillofacial region	Clinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region - EOST-OMS	Venous malformation in the oral and maxillofacial region Sclerotherapy, Venous malformation, ethanolamine oleate;angioma, venous	Single arm study, open (masking not used), no assignment All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.) 1. Local anesthesia into the lesion. 2. Puncture with 22-24G needle and confirm the backflow of blood. 3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.) 4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible. 5. Check the hemostasis of the injection point(s).	Danjo Atsushi	NULL	Recruiting	Not applicable	Not applicable	Both	25	Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs071180067

23/10/2009

20/03/2019

Clinical research of intralesional sclerotherapy in the oral and maxillofacial region

Clinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region - EOST-OMS

Venous malformation in the oral and maxillofacial region
Sclerotherapy, Venous malformation, ethanolamine oleate;angioma, venous

Single arm study, open (masking not used), no assignment
All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.)
1. Local anesthesia into the lesion.
2. Puncture with 22-24G needle and confirm the backflow of blood.
3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.)
4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible.
5. Check the hemostasis of the injection point(s).

Danjo Atsushi

NULL

Recruiting

Not applicable

Both

Phase 2

Japan